Patents by Inventor Howard Weiner

Howard Weiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190276892
    Abstract: Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.
    Type: Application
    Filed: January 18, 2019
    Publication date: September 12, 2019
    Inventors: Howard Weiner, Oleg Butovsky, Merit Cudkowicz, James Berry
  • Patent number: 10184151
    Abstract: Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 22, 2019
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Howard Weiner, Oleg Butovsky, Merit Cudkowicz, James Berry
  • Publication number: 20180155414
    Abstract: Methods for treating neurologic diseases, e.g., amyotrophic lateral sclerosis (ALS) and multiple sclerosis, by modulating the APOE-TGFbeta pathway. The methods include administering one or more inhibitory nucleic acids targeting Trem2 and/or ApoE), sense nucleic acids encoding Egr1 and/or Mertk, and/or antibodies that bind to and inhibit Trem2 and/or ApoE.
    Type: Application
    Filed: September 8, 2017
    Publication date: June 7, 2018
    Inventors: Oleg Butovsky, Susanne Krasemann, Charlotte Madore, Howard Weiner
  • Publication number: 20180125971
    Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.
    Type: Application
    Filed: October 12, 2017
    Publication date: May 10, 2018
    Inventors: Howard Weiner, Francisco J. Quintana
  • Patent number: 9927437
    Abstract: As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: March 27, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Francisco J. Quintana, Lior Mayo, Howard Weiner, Reza Halse
  • Patent number: 9895440
    Abstract: Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: February 20, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Francisco J. Quintana
  • Publication number: 20180023142
    Abstract: Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA has-miR-155.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 25, 2018
    Inventors: Howard Weiner, Oleg Butovsky, Merit Cudkowicz, James Berry
  • Patent number: 9850305
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 26, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Mohamed H. Sayegh
  • Publication number: 20170334977
    Abstract: Methods for treating neurologic diseases, e.g., amyotrophic lateral sclerosis (ALS) and multiple sclerosis, by modulating the APOE-TGFbeta pathway. The methods include administering one or more inhibitory nucleic acids targeting Trem2 and/or ApoE), sense nucleic acids encoding Egr1 and/or Mertk, and/or antibodies that bind to and inhibit Trem2 and/or ApoE.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 23, 2017
    Inventors: Oleg Butovsky, Susanne Krasemann, Charlotte Madore, Howard Weiner
  • Patent number: 9757448
    Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: September 12, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Ramot At Tel Aviv University Ltd.
    Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz
  • Publication number: 20160313324
    Abstract: As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.
    Type: Application
    Filed: December 12, 2014
    Publication date: October 27, 2016
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Francisco J. Quintana, Lior Mayo, Howard Weiner, Reza Halse
  • Publication number: 20150202231
    Abstract: Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient.
    Type: Application
    Filed: November 26, 2014
    Publication date: July 23, 2015
    Inventors: Howard Weiner, Francisco J. Quintana
  • Patent number: 9028798
    Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: May 12, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Francisco J. Quintana
  • Publication number: 20150064197
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Howard Weiner, Mohamed H. Sayegh
  • Patent number: 8962583
    Abstract: Methods of treating, reducing the risk of developing, or delaying the onset of an inflammatory disease are disclosed. The methods involved providing a subject with or at risk of developing an inflammatory disease and administering to the subject an effective amount of a first therapeutic composition comprising miR-124. Further provided are methods of diagnosing a subject with or at risk of developing an inflammatory disease.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: February 24, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Eugene Ponomarev, Tatyana Veremeyko, Anna M. Krichevsky
  • Publication number: 20140343095
    Abstract: Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARD-1).
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventors: Howard Weiner, Francisco J. Quintana, Mauricio Farez
  • Publication number: 20140235697
    Abstract: The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the rate of disease progression in a subject having a neurodegenerative disorder, selecting a subject for treatment of a neurodegenerative disorder, selecting a subject for participation in a clinical study, and determining the efficacy of treatment of a neurodegenerative disorder. These methods include determining the level of one or more microRNAs and/or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16? or CD14+CD16? monocyte) or in cerebrospinal fluid (CSF) from the subject and comparing the level of the one or more microRNAs and/or the level of the one or more inflammatory markers with a reference level(s).
    Type: Application
    Filed: October 11, 2012
    Publication date: August 21, 2014
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Oleg Butovsky
  • Publication number: 20140178367
    Abstract: Methods of treating inflammatory diseases, e.g., diseases associated with inflammatory CD14+/CD16? monocytes, e.g., amyotrophic lateral sclerosis (ALS), stroke, and glaucoma, using compounds such as small molecules and antibodies that target CCR2 or CCL2.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 26, 2014
    Applicant: THE Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Oleg Butovsky
  • Publication number: 20130336993
    Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.
    Type: Application
    Filed: January 18, 2013
    Publication date: December 19, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Howard Weiner, Francisco J. Quintana
  • Publication number: 20130183245
    Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.
    Type: Application
    Filed: February 24, 2011
    Publication date: July 18, 2013
    Applicants: TEL AVIV UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz